These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29187883)

  • 21. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
    Boothman AM; Scott M; Ratcliffe M; Whiteley J; Dennis PA; Wadsworth C; Sharpe A; Rizvi NA; Garassino MC; Walker J
    J Thorac Oncol; 2019 Aug; 14(8):1390-1399. PubMed ID: 31063864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death ligand 1 expression and CD8
    Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
    Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters.
    Garg G; Prasad KT; Singh N; Gupta P; Muthu V; Das A; Bal A
    J Pathol Transl Med; 2021 Nov; 55(6):398-405. PubMed ID: 34610234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Kinoshita T; Yamada K; Sasada T; Akiba J; Hoshino T
    Oncotarget; 2017 Sep; 8(37):61618-61625. PubMed ID: 28977890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.
    Li X; Xu Z; Cui G; Yu L; Zhang X
    Onco Targets Ther; 2020; 13():215-224. PubMed ID: 32021268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
    Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
    J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
    Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
    Song P; Guo L; Li W; Zhang F; Ying J; Gao S
    J Immunother; 2019 Jan; 42(1):23-28. PubMed ID: 30407231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression.
    Nagano M; Saito K; Kozuka Y; Ichishi M; Yuasa H; Noro A; Imai N; Shibusawa M; Kimoto M; Ishitobi M; Tono Y; Oda H; Ishihara M; Mizuno T; Ogawa T; Katayama N
    Oncol Lett; 2021 Jan; 21(1):36. PubMed ID: 33262828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
    Lin G; Fan X; Zhu W; Huang C; Zhuang W; Xu H; Lin X; Hu D; Huang Y; Jiang K; Miao Q; Li C
    Oncotarget; 2017 Oct; 8(48):83986-83994. PubMed ID: 29137398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.
    Jia K; He Y; Dziadziuszko R; Zhao S; Zhang X; Deng J; Wang H; Hirsch FR; Zhou C; Yu H; Zhang L
    Transl Lung Cancer Res; 2019 Dec; 8(6):895-906. PubMed ID: 32010568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.